GSK plc Reports Transaction in Own Shares on March 25, 2026

TL;DR

**GSK is buying back its own stock, which is generally good news for shareholders!**

AI Summary

GSK plc filed a 6-K on March 25, 2026, reporting a "TRANSACTION IN OWN SHARES." This filing indicates that GSK is likely repurchasing its own stock, which can reduce the number of outstanding shares and potentially boost earnings per share. For investors, this matters because share buybacks can signal management's confidence in the company's valuation and can be a way to return value to shareholders, potentially supporting the stock price.

Why It Matters

This filing signals GSK plc is engaging in share buybacks, which can increase shareholder value by reducing the number of outstanding shares and potentially boosting earnings per share.

Risk Assessment

Risk Level: low — Share buybacks are typically a positive signal for investors, indicating financial health and a commitment to returning value.

Analyst Insight

A smart investor would view this as a positive signal, potentially indicating management's belief that the stock is undervalued and a commitment to returning capital to shareholders. It might warrant further investigation into the scale and duration of the buyback program.

Key Players & Entities

• GSK plc (company) — the filer of the 6-K
• 0001131399 (company) — GSK plc's CIK
• 2026-03-25 (date) — the filing date and period of report

Forward-Looking Statements

• GSK plc's share price may see positive sentiment due to the share repurchase activity. (GSK plc) — medium confidence, target: 2026-04-25
• The company's earnings per share (EPS) will likely increase in future reports due to a reduced share count. (GSK plc) — medium confidence, target: 2026-06-30

FAQ

Filing Documents

• a9710x.htm (6-K) — 8605KB
• 0001654954-26-002709.txt ( ) — 8606KB

From the Filing

IN OWN SHARES a9710x UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of March 2026   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .       Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase: 24 March 2026 Aggregate number of ordinary shares of  31¼  pence each purchased: 500,000 Lowest price paid per share (GBp): 1,933.00p Highest price paid per share (GBp): 1,967.00p Volume-weighted average price paid per share (GBp): 1,949.05p   The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 17 February 2026. Since 17 February 2026, the Company has purchased 14,511,521 ordinary shares.   Following the above purchase, the Company will hold 254,402,615 ordinary shares in treasury and have 4,061,773,663 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,061,773,663. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 6.26 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases Shares purchased:   GSK plc (ISIN: GB00BN7SWP63) Date of purchases:     24 March 2026 Investment firm:         BNP Paribas SA   Aggregated information per trading venue: Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   38,394   1,967.00p   1,933.00p   1,949.83p   CHIX   152,921   1,967.00p   1,933.50p   1,949.44p   XLON   308,685   1,967.00p   1,933.00p   1,948.77p       Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   166   1942.0   CHIX   24-Mar-2026   08:00:25   20260324181169787   87   1942.0   CHIX   24-Mar-2026   08:00:26   20260324181169799   81   1941.5   BATE   24-Mar-2026   08:00:26   20260324181169801   42   1942.0   BATE   24-Mar-2026   08:00:26   20260324181169803   211   1941.5 &#

View Full Filing

View this 6-K filing on SEC EDGAR